![]() This long follow-up emphasizes that the greatest benefit from tepotinib plus gefitinib is derived by patients with MET amplification, who showed substantially improved progression-free and overall survival versus chemotherapy in this updated analysis. We present final analyses from the phase II part of INSIGHT, evaluating tepotinib (a once-daily, highly selective MET inhibitor) plus gefitinib versus chemotherapy in patients with EGFR-mutant NSCLC and MET-driven EGFR inhibitor resistance, with a median follow-up duration of 57.5 months. There is a high unmet need for patients with EGFR-mutant non–small cell lung cancer (NSCLC) that have developed resistance to EGFR inhibitors.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |